G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 478.2 INR 0.69% Market Closed
Market Cap: 417.1B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Glenmark Pharmaceuticals Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Pharmaceuticals Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Operating Expenses
-â‚ą69B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
-7%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Operating Expenses
-â‚ą140B
CAGR 3-Years
-12%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Operating Expenses
-â‚ą121.4B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Operating Expenses
-â‚ą285.7B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
-11%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Operating Expenses
-â‚ą56.9B
CAGR 3-Years
-12%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
M
Mankind Pharma Ltd
NSE:MANKIND
Operating Expenses
-â‚ą47.9B
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
417.1B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

GLENMARK Intrinsic Value
1 029.95 INR
Overvaluation 30%
Intrinsic Value
Price
G

See Also

What is Glenmark Pharmaceuticals Ltd's Operating Expenses?
Operating Expenses
-69B INR

Based on the financial report for Jun 30, 2024, Glenmark Pharmaceuticals Ltd's Operating Expenses amounts to -69B INR.

What is Glenmark Pharmaceuticals Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-7%

Over the last year, the Operating Expenses growth was 39%. The average annual Operating Expenses growth rates for Glenmark Pharmaceuticals Ltd have been -6% over the past three years , -5% over the past five years , and -7% over the past ten years .

Back to Top